QIAGEN launches standardized solutions for molecular analysis of FFPE samples
Hilden, Germany and Germantown, MD - November 4, 2010 - QIAGEN has launched several new products that assist in the molecular analysis of formalin-fixed, paraffin-embedded (FFPE) tissue samples. The new offering provides scientists with a range of dedicated kits over the whole FFPE workflow, from the isolation of DNA and total RNA, the setup of RT-PCR reactions through to bisulfite kits for applications in epigenetics research.
The portfolio extension is supported by a new brochure "Unlocking your FFPE Archive" that describes critical factors for molecular analysis of FFPE samples from preparation and storage to retrieval and analysis, as well as downstream applications such as reverse transcription and real-time PCR. It can be downloaded at http://www.qiagen.com/mc/sampletechnologies/ffpe.aspx.
The new kits include the AllPrep DNA/RNA FFPE Kit for purification of DNA and RNA from the same sample, the RNeasy® FFPE Kit for gDNA free isolation of RNA, as well as the miRNeasy FFPE Kit for the isolation of miRNA. The new QuantiFast Probe RT-PCR kits are tailored for gene expression analysis of FFPE samples with highly fragmented starting material and the EpiTect Plus Bisulfite Kits for epigenetics research. A deparaffinization solution also has been launched that is used to prepare the samples prior to purification of nucleic acids.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.